GSK (GSK) SEC filings

GSK's latest annual report is a Form 20-F filed on March 6, 2026 for the period ended December 31, 2025. Its latest Form 6-K report was filed on November 17, 2026. EDGAR lists 293 filings for it in the last twelve months.

Key facts

Latest annual report
20-F, Mar 6, 2026
Latest 6-K
6-K, Nov 17, 2026
Filings, last 12 months
293
Insider forms, last 12 months
1Forms 3, 4 and 5
13D and 13G, last 12 months
3
SEC central index key
0001131399

Filings as listed by SEC EDGAR at (re-read at most hourly). Source: SEC EDGAR filings for CIK 0001131399. Every form links to its document on sec.gov. Older filings are in EDGAR's archive; the tables here cover its recent list (at least the last year).

Annual and quarterly reports

GSK: annual and quarterly reports filed with the SEC
FormFiledPeriod endedDocument
20-FAnnual report of a foreign private issuer
20-FAnnual report of a foreign private issuer
20-FAnnual report of a foreign private issuer
20-F (amended)Annual report of a foreign private issuer
20-FAnnual report of a foreign private issuer

Amended reports are marked. The period is the fiscal year or quarter the report covers.

Reports of a foreign private issuer (Form 6-K)

GSK: reports on Form 6-K
FormFiledReport dateDocument
6-KDIRECTOR/PDMR SHAREHOLDING
6-KBEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION
6-KDIRECTOR/PDMR SHAREHOLDING
6-KGSK PUBLISHES PROVISIONAL DIVIDEND DATES
6-KTOTAL VOTING RIGHTS
6-K3RD QUARTER RESULTS
6-KRIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA
6-KDIRECTOR/PDMR SHAREHOLDING
6-KJEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE
6-KPOSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER
6-KUS FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B
6-KJEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER
6-KRIS-REZ POSITIVE EARLY DATA IN LUNG CANCER
6-KDIRECTOR/PDMR SHAREHOLDING
6-KDIRECTOR/PDMR SHAREHOLDING
6-KDIRECTOR/PDMR SHAREHOLDING
6-KDIRECTOR/PDMR SHAREHOLDING
6-KWENDY BECKER CBE - NEW DIRECTORSHIP
6-KADMISSION TO TRADING
6-KTOTAL VOTING RIGHTS

The latest 20 of 908 in EDGAR's recent list. A 6-K carries what the company publishes at home — results, press releases, notices to shareholders.

Insider forms (3, 4 and 5)

GSK: insider forms 3, 4 and 5 filed per month over the last twelve months
MonthForms filed
Nov 20260
Oct 20260
Sep 20260
Aug 20260
Jul 20260
Jun 20260
May 20260
Apr 20260
Mar 20260
Feb 20260
Jan 20260
Dec 20251
GSK: the latest insider forms
FormFiledTransaction date
4
4
4
3
3
3
4

Each form is filed by the insider about their own holding; the trade details are inside the form on sec.gov. Counts include amendments. The current month is counted to date.

Ownership reports (Schedules 13D and 13G)

GSK: Schedule 13D and 13G beneficial ownership reports
FormFiledEvent date
Schedule 13G (amended)—
Schedule 13G—
Schedule 13D (amended)—
Schedule 13D—
Schedule 13D (amended)—
Schedule 13G (amended)—
Schedule 13D (amended)—
Schedule 13G (amended)—
Schedule 13D (amended)—
Schedule 13G (amended)—
Schedule 13D (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13D (amended)—
Schedule 13D (amended)—
Schedule 13D (amended)—
Schedule 13D (amended)—
Schedule 13D (amended)—
Schedule 13G (amended)—
Schedule 13G—

The latest 20 of 26 in EDGAR's recent list. Filed by the holder, not the company. EDGAR's list names the form and date; who filed it is in the document.

Everything else (55 filings: registrations, prospectuses, Rule 144 notices, correspondence and more)
GSK: other SEC filings
FormFiledPeriodDocument
13F-HR
S-8—Registration statement for employee plans
CERT—NYSE CERTIFICATION
8-A12B—
424B2—Prospectus
FWP—
424B2—Prospectus
144—Notice of proposed sale
13F-HR
SC TO-T (amended)—
SC TO-T (amended)—
SC TO-T (amended)—
SC TO-T (amended)—
SC TO-T—
11-K
11-K
SC TO-C—
SC TO-C—
SC TO-C—
SD—SPECIALIZED DISCLOSURE REPORT
13F-HR
IRANNOTICE—
SC TO-T (amended)—
SC TO-T (amended)—
13F-HR
SC TO-T—
SC TO-C—
SC TO-C—
11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS
SD—SPECIALIZED DISCLOSURE REPORT
25-NSE—
CERT—NYSE CERTIFICATION
CERT—NYSE CERTIFICATION
8-A12B—
8-A12B—
424B2—Prospectus
FWP—
424B2—Prospectus
IRANNOTICE—
11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
25-NSE—
SD—SPECIALIZED DISCLOSURE REPORT
F-3ASR—
IRANNOTICE—
25-NSE—
11-KANNUAL REPORT
11-KANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
SD—SPECIALIZED DISCLOSURE
EFFECT—
POS AM—
IRANNOTICE—
25-NSE—
25-NSE—

What the forms are

Form 3 — Initial statement of beneficial ownership
An insider's first statement of holdings in the company's equity securities. Insiders are officers, directors and holders of more than 10 percent of a class of its registered equity securities.
Form 4 — Statement of changes in beneficial ownership
An insider's transactions in the company's equity securities, disclosed within two business days of the transaction.
Form 144 — Notice of proposed sale
In the SEC's Forms Index: notice of proposed sale of securities pursuant to Rule 144.
Form 10-K — Annual report
Audited annual financial statements, a discussion of material risk factors, and management's discussion and analysis of the results for the prior fiscal year.
Form 10-Q — Quarterly report
Unaudited quarterly financial statements, updates on material risks, and management's discussion and analysis of the results for the prior fiscal quarter.
Form 8-K — Current report
Discloses material events or information the company chooses or is required to make public before its next scheduled quarterly or annual report. Each report lists the items it covers.
Form 20-F — Annual report of a foreign private issuer
Audited financial statements of the foreign private issuer and a discussion of its financial results; the same form is used to register a class of securities.
Form 6-K — Report of a foreign private issuer
Filed with press releases, communications to security holders, and disclosures the company's home country requires it to make to security holders.
Schedule 13D — Schedule 13D beneficial ownership report
Filed when a party acquires more than five percent of a class of the company's registered voting securities; also used to disclose later changes to the holding.
Schedule 13G — Schedule 13G beneficial ownership report
Filed when a party acquires more than five percent of a class of the company's registered voting securities as a passive investment.
Form S-8 — Registration statement for employee plans
In the SEC's Forms Index: registration statement under the Securities Act of 1933 for securities to be offered to employees under certain plans.
Form 424B — Prospectus
A document disclosing information about the company and an offering; it typically makes up a large part of the registration statement.
Form SD — Specialized disclosure report
In the SEC's Forms Index: Specialized Disclosure Report.

From the SEC's own descriptions: SEC, Using EDGAR to Research Investments; SEC, Forms Index; SEC, Form 8-K and its items (PDF).

Questions and answers

Where is GSK's latest annual report (20-F)?

GSK filed its latest Form 20-F with the SEC on March 6, 2026 for the period ended December 31, 2025. The table of annual and quarterly reports on this page links to the document on sec.gov.

How many insider filings (Forms 3, 4 and 5) were there for GSK in the last year?

1 insider form in the twelve months to November 18, 2026, the latest a Form 4 filed on December 15, 2025. Officers, directors and holders of more than 10 percent of a class of the company's registered equity securities must disclose their holdings and transactions; a Form 4 is due within two business days of a trade.

Has anyone reported owning more than 5% of GSK?

EDGAR lists 3 Schedule 13D or 13G filings about GSK in the last twelve months, the latest on August 13, 2026. These are filed by a party that acquires more than five percent of a class of the company's voting securities; 13G is for passive investors.

Cite this page

Funkfolio, “GSK SEC filings: latest 20-F and 6-K reports”, data as of 18 November 2026. https://funkfolio.com/stock/GSK/filings

Underlying data: SEC EDGAR submissions (data.sec.gov).